Skip to main content
Back to News
Finnish healthtech MultivisionDx has raised 1 million EUR in pre-seed funding to commercialize AI-dr...
Funding
1 min read
FI

Finnish healthtech MultivisionDx has raised 1 million EUR in pre-seed funding to commercialize AI-dr...

The AMW Read

This is an incremental update regarding a new entrant in the AI-driven spatial biology diagnostics sub-sector of Vertical AI Healthcare/Bio.
NoveltySignificance
Healthcare & Bio · Player Map

Finnish healthtech MultivisionDx has raised 1 million EUR in pre-seed funding to commercialize AI-driven spatial biology diagnostics. Spun out from the University of Helsinki, the platform creates patient-specific fingerprints by analyzing tumor microenvironments. Following a successful 650-patient proof-of-concept, the startup aims to transition these tools into routine clinical use within 18 months. This shift toward automated pathology aims to eliminate oncology therapy trial-and-error. 🧬...

How This Connects

Based on Healthcare & Bio · Player Map

  1. 2d agoIsomorphic Labs explores funding at a valuation of at least $40 billionIsomorphic Labs
  2. 1w agoApheris and Ginkgo launch antibody AI consortium with four pharma companiesApheris
  3. 1w agoEnveda raises $311 million to advance AI-discovered natural-molecule drugsEnveda
  4. 3w agoLevel Five, a game developer, has issued a public apology after facing criticism for what it called...Level Five
  5. 9mo agoFinnish healthtech MultivisionDx has raised 1 million EUR in pre-seed funding to commercialize AI-dr... · THIS ARTICLE

More news from MultivisionDx

Stay updated with the latest news and announcements from MultivisionDx.

View all MultivisionDx news

Discover AI Startups

Explore 5,000+ AI companies with VC-grade analysis, funding data, and investment insights.

Explore Dashboard